Literature DB >> 17406536

Biochemical assays for multiple activation states of protein kinase C.

Toshiyoshi Yamamoto1, Hidenori Matsuzaki, Shinji Kamada, Yoshitaka Ono, Ushio Kikkawa.   

Abstract

This protocol describes biochemical procedures to monitor the activation of the protein kinase C (PKC) family using PKCdelta as the representative. The PKC family is composed of ten isoforms divided into cPKC, nPKC and aPKC groups, and their catalytic activity is regulated by multiple mechanisms. For example, PKCdelta in the nPKC group is activated by diacylglycerol as a second messenger in the receptor-coupled manner, through tyrosine phosphorylation and protein complex formation in stress-stimulated cells, and by the caspase-catalyzed cleavage during apoptosis. The isoform is immunoprecipitated from cultured cells, the protein kinase activity is measured by in vitro kinase assay and the tyrosine phosphorylation and protein complex formation are characterized by immunoblot, whereas the generation of the catalytic fragment is detected by immunoblot in the cell extract. The combination of these procedures is useful to evaluate the activation states of the PKC family in cells. This protocol can be completed in 3-5 d.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17406536     DOI: 10.1038/nprot.2006.420

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  2 in total

1.  Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer.

Authors:  Navjotsingh Pabla; Guie Dong; Man Jiang; Shuang Huang; M Vijay Kumar; Robert O Messing; Zheng Dong
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.

Authors:  Kun-Yi Lai; Ya-Ching Chou; Jiun-Han Lin; Yi Liu; Kai-Min Lin; Shin-Lian Doong; Mei-Ru Chen; Te-Huei Yeh; Sue-Jane Lin; Ching-Hwa Tsai
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.